DOCSLIB.ORG

ICD-10: Major Differences for Five Common Diagnoses

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ICD-10: Major Differences for Five Common Diagnoses CME Cindy Hughes, CPC, CFPC ICD-10: Major Differences for Five Common Diagnoses Test your knowledge of ICD-10 coding E11.65, Type 2 diabetes mellitus with hyperglycemia and documentation requirements for five diagnoses you’re likely to encounter in family medicine. he time has come. Are you ready for the Oct. 1 A. Diagnosis codes support the medical necessity transition to ICD-10 diagnosis coding? If you are of services provided. not sure, you are not alone. Many elements of B. Diagnosis codes support claims payment. this transition have depended on your software C. Diagnosis data is increasingly used to evaluate T vendors, clearinghouses, payers, and staff, but there is one cost and quality of care. thing you can control: your documentation of the informa- D. Diagnosis data is used to influence public tion necessary to support the diagnosis codes you choose to health policy. bill. Your documentation probably does not need a major E. All of the above. overhaul, but you will need to be more specific and detailed Answer: The diagnosis codes reported on physician in certain areas. In this article, we will look at the documen- claims must be supported not only to facilitate payment tation elements required to support ICD-10 code selection, but also because they become the data upon which deci- focusing on five common conditions in family medicine. sions beyond claims payment are made. The correct answer Quizzes will test your knowledge throughout the article. to the above question, then, is E, all of the above. Documentation that supports specific diagnosis coding also may alleviate burdensome medical record requests First, why should you care? from third parties. Take for instance the following state- The increased specificity required in your documentation ment a physician forwarded to me from a claims admin- and coding under ICD-10 may seem unnecessarily bur- istrator regarding medical record requests to support risk densome. However, diagnosis coding has a wider impact adjustment: “ICD-9-CM (or its successor ICD-10-CM) than you might immediately recognize. diagnosis codes determine a patient’s risk score. The more Question: In which of the following ways does diagno- diagnosis detail submitted with claims and encounters, the sis coding affect physician practices and patient care? less likelihood that [insurer name redacted] will need to About the Author Cindy Hughes is an independent coding consultant based in El Dorado, Kan., and a contributing editor to Family Practice Management. Author disclosure: no relevant financial affiliations disclosed. Downloaded from the Family Practice Management website at www.aafp.org/fpm. Copyright © 2015 American Academy of Family Physicians. For theSeptember/October private, noncommercial 2015 | usewww.aafp.org/fpm of one individual | FAMILY user of PRACTICE the website. MANAGEMENT | 15 © CHRISTINE SCHNEIDER CHRISTINE © All other rights reserved. Contact [email protected] for copyright questions and/or permission requests. request and audit medical records.” In other not support a more specific diagnosis. The words, if your documentation supports the guidelines state, “It would be inappropriate to level of service coded and the selected diagnosis select a specific code that is not supported by codes specifically identify the nature of your the medical record documentation or conduct patient’s condition, you are less likely to receive medically unnecessary diagnostic testing in a request for your medical record. If a request order to determine a more specific code.” is made, your documentation will support both Other important documentation guidelines Your documenta- the service provided and why it was provided. include the following: tion may not need an overhaul for • List first a disease and then associated manifestations, ICD-10, but it What to report will need to be • Link sequelae (late or residual conditions) more specific and Before we review common diagnoses, it is to the history of an injury or past medical detailed in certain important to know when codes should and condition, areas. should not be reported for a condition. • Report personal or family history codes Question: According to the official guide- when the history affects care or influences lines for ICD-10, which of the following con- treatment. ditions should be reported? For asthma, be A. All conditions listed in the problem list. Five common diagnoses sure to document B. Only conditions with confirmed and the classification differential diagnoses. With so many diagnoses in primary care, it (e.g., intermittent) C. All conditions that require or affect makes sense to focus your ICD-10 education and the status (e.g., with exacerbation). patient care or treatment at the time of the efforts on those that are common in your spe- encounter. cialty. The National Center for Health Statis- D. Only the condition related to the chief tics provides this data.1 complaint. Question: Which condition is the top If you don’t docu- E. Conditions that are probable. reason for office or other outpatient visits to ment these details, Answer: The ICD-10 guidelines (like family physicians? you must report ICD-9) specify that physicians should not A. Diabetes. code J45.909, report the following: B. Hypertension. unspecified and • Conditions documented as probable, C. Otitis media. uncomplicated likely, or to be ruled-out (rules differ for D. Asthma. asthma. facilities), E. Well-child examinations. • Codes for symptoms that are integral to Answer: All of the above conditions are an established diagnosis, near the top of the list for family medicine, but • Conditions that are no longer present, for the number one diagnosis, you’ll have to • Conditions that did not affect manage- read on. Let’s take a look at five commonly ment or treatment at the current encounter. reported diagnoses and their documentation Therefore, the answer to the question is requirements under ICD-10. C. All conditions that require or affect patient care or treatment at the time of the encoun- Number five: asthma ter should be reported. Physi- Asthma classification in ICD-10 mirrors J45.41, Moderate cians should the guidelines from the National Asthma persistent asthma with list first the Education and Prevention Program, which acute exacerbation condition that is differs from ICD-9.2 chiefly respon- Question: Which of the following is not sible for the services provided and code what an option for the classification of asthma in is known at the time of the encounter. ICD-10? This instruction to code what is known at A. Intrinsic. the time of the encounter is important. Based B. Mild intermittent. on this guideline, physicians should report C. Mild persistent. unspecified codes such as J12.9, unspeci- D. Moderate persistent. fied viral pneumonia, when the information E. Severe persistent. known at the time of the encounter does Answer: All of the above classifications are 16 | FAMILY PRACTICE MANAGEMENT | www.aafp.org/fpm | September/October 2015 ICD-10 COMMON DX options in ICD-10 except A, intrinsic. That in a disease classified elsewhere) would sup- was the old terminology used in ICD-9. port code H66.93 (otitis media, unspecified, In addition to documenting the asthma bilateral). But better documentation, such classification, physicians should document as acute recurrent the status of the condition at each encoun- bilateral suppurative H65.01 Acute serous ter. “Table one: Documentation elements for otitis media without asthma” (page 18) includes the codes for each spontaneous rupture otitis media, right ear asthma classification by status. of the ear drum If you were to document asthma without (H66.006), may help to identify the need for specifying the classification or status, that higher levels of medical decision-making or would be reported with code J45.909, unspeci- additional services. (See “Table two: Docu- fied and uncomplicated asthma. However, mentation elements for otitis media,” page 18.) consider the implications of reporting J45.909 for a patient who is not compliant with control Number three: diabetes medications, is seen for an acute exacerbation, and requires a revised care plan. This code not Key documentation elements for diabetes are only fails to identify the nature of the patient the type of diabetes, manifestations of the dis- presentation but also fails to convey the assess- ease, and use of insulin (not necessary for type ment of the asthma status and the complicat- 1 diabetes). “Table three: Documentation ele- ing factor of noncompliance. Documenting a ments for diabetes” (page 18) illustrates the bit more detail – moderate persistent asthma requirements. with exacerbation, J45.41 – better conveys the Question: Which of the following docu- nature of the encounter. Code Z91.14 could mentation elements would be required to be added to specify the patient’s poor compli- accurately code an encounter with a patient ance with control medication and explain the who has diabetes, loss of protective sensation, patient management complications. a foot ulcer, and an elevated A1C result? A. Type of diabetes. When document- ing otitis media, B. Location of the ulcer. Number four: otitis media don’t forget the C. Related conditions (manifestations). new requirement Both ICD-9 and ICD-10 provide codes to spe- D. Condition status/characteristics (e.g., to specify lateral- cifically identify otitis media as acute or chronic uncontrolled). ity (right, left, or and as serous, allergic, or suppurative. Despite E. All of the above. bilateral). the availability
Load more

Recommended publications
  • Cardiac Involvement in COVID-19 Patients: a Contemporary Review
    Review Cardiac Involvement in COVID-19 Patients: A Contemporary Review Domenico Maria Carretta 1, Aline Maria Silva 2, Donato D’Agostino 2, Skender Topi 3, Roberto Lovero 4, Ioannis Alexandros Charitos 5,*, Angelika Elzbieta Wegierska 6, Monica Montagnani 7,† and Luigi Santacroce 6,*,† 1 AOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Coronary Unit and Electrophysiology/Pacing Unit, Cardio-Thoracic Department, Policlinico University Hospital of Bari, 70124 Bari, Italy; [email protected] 2 AOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Cardiac Surgery, Policlinico University Hospital of Bari, 70124 Bari, Italy; [email protected] (A.M.S.); [email protected] (D.D.) 3 Department of Clinical Disciplines, School of Technical Medical Sciences, University of Elbasan “A. Xhuvani”, 3001 Elbasan, Albania; [email protected] 4 AOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Clinical Pathology Unit, Policlinico University Hospital of Bari, 70124 Bari, Italy; [email protected] 5 Emergency/Urgent Department, National Poisoning Center, Riuniti University Hospital of Foggia, 71122 Foggia, Italy 6 Department of Interdisciplinary Medicine, Microbiology and Virology Unit, University of Bari “Aldo Moro”, Piazza G. Cesare, 11, 70124 Bari, Italy; [email protected] 7 Department of Biomedical Sciences and Human Oncology—Section of Pharmacology, School of Medicine, University of Bari “Aldo Moro”, Policlinico University Hospital of Bari, p.zza G. Cesare 11, 70124 Bari, Italy; [email protected] * Correspondence: [email protected] (I.A.C.); [email protected] (L.S.) † These authors equally contributed as co-last authors. Citation: Carretta, D.M.; Silva, A.M.; D’Agostino, D.; Topi, S.; Lovero, R.; Charitos, I.A.; Wegierska, A.E.; Abstract: Background: The widely variable clinical manifestations of SARS-CoV2 disease (COVID-19) Montagnani, M.; Santacroce, L.
    [Show full text]
  • Idiopathic Isolated Right Ventricular Apical Hypertrophy
    Acta Cardiol Sin 2018;34:288-290 Letter to the Editor doi: 10.6515/ACS.201805_34(3).20180122A Idiopathic Isolated Right Ventricular Apical Hypertrophy Debika Chatterjee1 and Pradeep Narayan2 INTRODUCTION creased RV compliance or RV dysfunction. Isolated right ventricular hypertrophy is extremely rare and reports in the literature are very sparse. We re- DISCUSSION port a case of focal apical right ventricular hypertrophy without involvement of the left ventricular cavity or the RV hypertrophy is usually reported in association inter-ventricular septum. with left ventricular hypertrophy which in turn could be secondary to hypertrophic cardiomyopathy (HCM), hy- pertensive left ventricular hypertrophy (LVH) or other CASE infiltrative conditions.1 However, isolated involvement of right ventricle is extremely rare in these conditions. The A 50 year old male, asymptomatic, normotensive only situation where isolated RV hypertrophy is seen is in patient on routine medical evaluation was found to have presence of idiopathic pulmonary artery hypertension. inverted T-waves on the electrocardiogram (Figure 1). However, the hypertrophy in these cases is rarely focal. He had no history of angina or any other symptoms. Isolated apical hypertrophic cardiomyopathy is an However, despite complete lack of symptoms, because extremely unusual nonobstructive hypertrophy that is of the abnormality on the electrocardiography (ECG) an localized to the cardiac apex.2 Even in these cases spar- echocardiography was carried out for further evaluation. ing of the left ventricular apex with involvement of only Echocardiography revealed focal hypertrophy of the the right ventricular apex is even more uncommon. The right ventricular (RV) apex almost obliterating the apex most common presenting symptom in patients with api- (Figure 2A) but sparing the inter-ventricular septum.
    [Show full text]
  • Mitral Valve Disease in Dogs- Truly Epic Kristin Jacob, DVM, DACVIM CVCA Cardiac Care for Pets Towson, MD
    Mitral Valve Disease in Dogs- Truly Epic Kristin Jacob, DVM, DACVIM CVCA Cardiac Care for Pets Towson, MD Chronic degenerative mitral valvular disease (DMVD) is the most common heart disease in dogs. In dogs with congestive heart failure, 75% have mitral regurgitation/degenerative valvular disease. Almost all have tricuspid regurgitations as well, but clinically the mitral regurgitation is the most significant. Degenerative valvular disease is most common in small breed dogs and more common in males than females. DMVD has been proven to be inherited in the Cavalier King Charles Spaniel and the Dachshund but several other breeds are predisposed, such as Bichons, poodles, Chihuahuas, Miniature Schnauzers, Boston Terriers. The cause of degenerative valvular disease remains unknown. However, the valve changes occur due to a destruction of collagen, deposition of mucopolysaccharide in the spongiosa and fibrosa layer of mitral valve, which also affects chordae tendinea. These changes prevent effective coaptation of the valve leaflets leading to progressive mitral regurgitation. Mitral regurgitation (MR) leads to decreasing forward output and increasing left atrial and left ventricular dilation and remodeling as well as activation of the neurohormonal systems. Typically, patients will have 2-3 years in asymptomatic phase (time between when heart murmur detected) until symptoms develop - congestive heart failure (CHF). We can detect progressive heart enlargement 6-12 months prior to the development of CHF. This means that we have a fairly long time period to intervene with therapy and alter the progression of the disease - we know what’s coming! Eventually left atrial pressure increases sufficiently and pulmonary congestion develops leading to symptoms of CHF and can also lead to pulmonary hypertension.
    [Show full text]
  • Clinical Manifestation and Survival of Patients with I Diopathic Bilateral
    ORIGINAL ARTICLE Clinical Manifestation and Survival of Patients with Mizuhiro Arima, TatsujiI diopathicKanoh, Shinya BilateralOkazaki, YoshitakaAtrialIwama,DilatationAkira Yamasaki and Sigeru Matsuda Westudied the histories of eight patients who lacked clear evidence of cardiac abnormalities other than marked bilateral atrial dilatation and atrial fibrillation, which have rarely been dis- cussed in the literature. From the time of their first visit to our hospital, the patients' chest radio- graphs and electrocardiograms showed markedly enlarged cardiac silhouettes and atrial fibrilla- tion, respectively. Each patient's echocardiogram showed a marked bilateral atrial dilatation with almost normal wall motion of both ventricles. In one patient, inflammatory change was demonstrated by cardiac catheterization and endomyocardial biopsy from the right ventricle. Seven of our eight cases were elderly women.Over a long period after the diagnosis of cardiome- galy or arrhythmia, diuretics or digitalis offered good results in the treatment of edema and congestion in these patients. In view of the clinical courses included in the present study, we conclude that this disorder has a good prognosis. (Internal Medicine 38: 112-118, 1999) Key words: cardiomegaly, atrial fibrillation, elder women,good prognosis Introduction echocardiography. The severity of mitral and tricuspid regur- gitation was globally assessed by dividing into three equal parts Idiopathic enlargement of the right atrium was discussed by the distance from the valve orifice. The regurgitant jet was de- Bailey in 1955(1). This disorder may be an unusual congenital tected on color Doppler recording in the four-chamber view malformation. A review of the international literature disclosed and classified into one of the three regions (-: none, +: mild, that although several cases have been discussed since Bailey's ++:moderate, +++: severe).
    [Show full text]
  • Cardiac Hypertrophy, Hypertrophic Cardiomyopathy, and Hyperparathyroidism-An Association
    Br Heart J: first published as 10.1136/hrt.54.5.539 on 1 November 1985. Downloaded from Br HeartJ 1985; 54: 539-42 Cardiac hypertrophy, hypertrophic cardiomyopathy, and hyperparathyroidism-an association C SYMONS, F FORTUNE, R A GREENBAUM, P DANDONA From the Departments of Cardiology and Human Metabolism, the Royal Free Hospital, London SUMMARY Left ventricular hypertrophy (symmetric, asymmetric, or hypertrophic cardio- myopathy) is an almost invariable accompaniment of primary hyperparathyroidism. Five of 18 patients with hypertrophic cardiomyopathy had raised serum concentrations of parathyroid hor- mone with normal serum calcium concentrations. Left ventricular hypertrophy did not occur in any of the six patients with hypercalcaemia alone. These relations suggest that parathyroid hormone rather than a rise in the extracellular calcium concentration is associated with a spectrum of left ventricular hypertrophy. All patients with increased circulating parathyroid hormone concentrations should have echo- cardiographic examination of the left ventricle. Conversely, parathyroid hormone concentrations should be measured in all patients with left ventricular hypertrophy from an unknown cause, especially those with hypertrophic cardiomyopathy. copyright. Calcium has powerful positive inotropic and chro- included.) Sixteen of these patients were found to notropic effects on cardiac muscle.' Any factor that have primary hyperparathyroidism and six of these promotes transmembrane calcium flux could be had had operations to remove either a parathyroid
    [Show full text]
  • Hypertension and Arrhythmia
    2005; 6: No. 24 HYPERTENSION AND ARRHYTHMIA Jean-Philippe Bagueta, Serap Erdineb, Jean-Michel Malliona From aCardiology and Hypertension Department, Grenoble University Hospital, BP 217, 38043 Grenoble cedex 09, France and b Istanbul University Cerrahpasa School of Medicine, Göztepe I. Orta Sok, 34 A/9 Istanbul, Turkey Correspondence: Jean-Philippe Baguet, Cardiologie et Hypertension artérielle, CHU de Grenoble - BP 217, 38043 Grenoble Cedex 09, France, tel +334767654.40, fax 334767655.59, [email protected] Introduction rapid or if there is some underlying problem with left ventricular Arrhythmia-both atrial and ventricular-is a common comorbidity function (either systolic or diastolic) (10). AF can also cause with hypertension (HT). Underlying mechanisms are many and episodes of dizziness or even syncope. Finally, in the various, including left ventricular hypertrophy (LVH), myocardial Framingham study, a correlation was observed between AF and ischemia, impaired left ventricular function and left atrial enlarge- mortality in both sexes, and this independently of other variables ment. Any form of arrhythmia may be associated with LVH but (11). ventricular arrhythmia is more common as well as being more dangerous. Treatment of atrial arrhythmia Preventing AF in hypertensive subjects depends on controlling Atrial arrhythmia blood pressure in order to reduce the risk of hypertensive car- Prevalence diomyopathy (or at least mitigating the consequences thereof). After supraventricular extrasystole, atrial fibrillation (AF) is the Antihypertensive therapy has been shown to reverse some of the next most common form of arrhythmia associated with HT. The structural cardiac changes caused by HT, including LVH and atri- relative risk of developing AF in HT is modest compared with other al enlargement (12, 13).
    [Show full text]
  • Hypertrophic Cardiomyopathy: a Systematic Review
    CLINICAL CARDIOLOGY CLINICIAN’S CORNER Hypertrophic Cardiomyopathy A Systematic Review Barry J. Maron, MD Context Throughout the past 40 years, a vast and sometimes contradictory litera- ture has accumulated regarding hypertrophic cardiomyopathy (HCM), a genetic car- YPERTROPHIC CARDIOMYOP- diac disease caused by a variety of mutations in genes encoding sarcomeric proteins athy (HCM) is a complex and and characterized by a broad and expanding clinical spectrum. relatively common genetic Objectives To clarify and summarize the relevant clinical issues and to profile rap- cardiac disease that has been idly evolving concepts regarding HCM. Hthe subject of intense scrutiny and in- Data Sources Systematic analysis of the relevant HCM literature, accessed through vestigation for more than 40 years.1-10 Hy- MEDLINE (1966-2000), bibliographies, and interactions with investigators. pertrophic cardiomyopathy is an impor- Study Selection and Data Extraction Diverse information was assimilated into tant cause of disability and death in a rigorous and objective contemporary description of HCM, affording greatest weight patients of all ages, although sudden and to prospective, controlled, and evidence-based studies. unexpected death in young people is per- Data Synthesis Hypertrophic cardiomyopathy is a relatively common genetic car- haps the most devastating component of diac disease (1:500 in the general population) that is heterogeneous with respect to disease- its natural history. Because of marked causing mutations, presentation, prognosis, and treatment strategies. Visibility at- heterogeneity in clinical expression, tached to HCM relates largely to its recognition as the most common cause of sudden natural history, and prognosis,11-20 HCM death in the young (including competitive athletes).
    [Show full text]
  • Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Impact, and Management
    Heart Failure Reviews (2019) 24:189–197 https://doi.org/10.1007/s10741-018-9752-6 Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management Lohit Garg 1 & Manasvi Gupta2 & Syed Rafay Ali Sabzwari1 & Sahil Agrawal3 & Manyoo Agarwal4 & Talha Nazir1 & Jeffrey Gordon1 & Babak Bozorgnia1 & Matthew W. Martinez1 Published online: 19 November 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy characterized by left ventricular hyper- trophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is a common sustained arrhythmia in HCM patients and is primarily related to left atrial dilatation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardio- graphic (ECHO) features that have been associated with development of AF in HCM patients; strongest predictors are left atrial size, age, and heart failure class. AF can lead to progressive functional decline, worsening heart failure and increased risk for systemic thromboembolism. The management of AF in HCM patient focuses on symptom alleviation (managed with rate and/or rhythm control methods) and prevention of complications such as thromboembolism (prevented with anticoagulation). Finally, recent evidence suggests that early rhythm control strategy may result in more favorable short- and long-term outcomes. Keywords Atrial fibrillation . Hypertrophic cardiomyopathy . Treatment . Antiarrhythmic agents Introduction amyloidosis) [3–5]. The clinical presentation of HCM is het- erogeneous and includes an asymptomatic state, heart failure Hypertrophic cardiomyopathy (HCM) is the most common syndrome due to diastolic dysfunction or left ventricular out- inherited cardiomyopathy due to mutation in one of the sev- flow (LVOT) obstruction, arrhythmias (atrial fibrillation and eral sarcomere genes and transmitted in autosomal dominant embolism), and sudden cardiac death [1, 6].
    [Show full text]
  • Left Ventricular Remodeling in Hypertrophic Cardiomyopathy: an Overview of Current Knowledge
    Journal of Clinical Medicine Review Left Ventricular Remodeling in Hypertrophic Cardiomyopathy: An Overview of Current Knowledge Beatrice Musumeci, Giacomo Tini , Domitilla Russo, Matteo Sclafani, Francesco Cava, Alessandro Tropea, Carmen Adduci, Francesca Palano, Pietro Francia and Camillo Autore * Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, 00189 Rome, Italy; [email protected] (B.M.); [email protected] (G.T.); [email protected] (D.R.); [email protected] (M.S.); [email protected] (F.C.); [email protected] (A.T.); [email protected] (C.A.); [email protected] (F.P.); [email protected] (P.F.) * Correspondence: [email protected]; Tel.: +39-06-3377-5577 Abstract: While most patients with hypertrophic cardiomyopathy (HCM) show a relatively stable morphologic and clinical phenotype, in some others, progressive changes in the left ventricular (LV) wall thickness, cavity size, and function, defined, overall, as “LV remodeling”, may occur. The interplay of multiple pathophysiologic mechanisms, from genetic background to myocardial ischemia and fibrosis, is implicated in this process. Different patterns of LV remodeling have been recognized and are associated with a specific impact on the clinical course and management of the disease. These findings underline the need for and the importance of serial multimodal clinical and instrumental evaluations to identify and further characterize the LV remodeling phenomenon. A more complete definition of the stages of the disease may present a chance to improve the management of Citation: Musumeci, B.; Tini, G.; Russo, D.; Sclafani, M.; Cava, F.; HCM patients. Tropea, A.; Adduci, C.; Palano, F.; Francia, P.; Autore, C.
    [Show full text]
  • Hypertrophic Cardiomyopathy
    Clinical Update Adapted from: 2020 ACC/AHA Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy ACC/AHA Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care (Updated May 2019)* HCM Hypertrophic Cardiomyopathy (HCM) is a Globally Prevalent & Common Genetic Heart Disease Inheritance Pattern Sex Distribution Disease Prevalence Triggers for Evaluation +/- +/+ Symptoms 50% 50% Cardiac Event Heart Murmur +/- Abnormal EKG Women diagnosed Estimated Cardiac Imaging Autosomal Dominant less commonly 1:200 – 1:500 Family Studies Other non-HCM Causes of LV Hypertrophy ⅔ have LVOTO Metabolic & Multi-organ Syndromes RASopathies Mitochondrial myopathies LV Outflow Tract Glycogen / Lysosomal storage diseases Amyloidosis Obstruction Sarcoidosis (LVOTO) Hemochromatosis Danon disease Secondary Causes Athlete’s heart HCM ⅓ do not have LVOTO Hypertension Valvular & subvalvular stenosis Abbreviations: EKG, indicates electrocardiogram; RAS, reticular activating system. 3 Ommen, SR et al. 2020 ACC/AHA Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy. Circulation. XXX:XX-XX. HCM Defining Hypertrophic Cardiomyopathy in 2020 • Morphologic expression confined solely to the heart • Characterized by left ventricular (LV) hypertrophy Basal anterior septum in continuity with the anterior free wall = most common • No other cardiac, systemic or metabolic disease capable of producing the magnitude of hypertrophy
    [Show full text]
  • Changes in Cardiac Geometry Due to Hypertrophy
    Changes in Cardiac Geometry Due to Hypertrophy By Marta Ellen Pedersen A Master’s Paper Submitted in Partial Fulfillment of The Requirements for the Degree of Master of Science in Clinical Exercise Physiology Dr. Joseph O’ Kroy Date University of Wisconsin-River Falls 2014 Introduction For any given body size, men have larger hearts than women, athletes have larger hearts than nonathletes, and often times, an enlarged heart is a symptom of an underlying disorder that is causing the heart to work harder than normal. This review will emphasize the differences between a pathologically enlarged heart and an athletically enlarged heart. Pathologically induced hypertrophy (myopathy) When heart cells get bigger, (often is the case when heart disease is present) the total heart works less efficiently. Some people suffer from conditions like hypertrophic cardiomyopathy, which includes significant heart muscle enlargement, and can be genetic or caused by high blood pressure. Cardiomyopathy decreases the size of the heart's chambers, reducing blood flow. Hypertrophy, or thickening, of the heart muscle can occur in response to increased stress on the heart. The most common causes of Cardiomyopathy are related to increased blood pressure. The extra work of pumping blood against the increased pressure causes the ventricle to thicken over time, the same way a body muscle increases in mass in response to weightlifting. Cardiomyopathy can occur in both the right and left atrium and the right and left ventricles. Blood travels through the right ventricle to the lungs. If conditions occur that decrease pulmonary circulation, extra stress can be placed on the right ventricle, and can lead to right ventricular myopathy.
    [Show full text]
  • How to Estimate Left Ventricular Hypertrophy in Hypertensive Patients
    Review 389 How to estimate left ventricular hypertrophy in hypertensive patients Dragan Lovic, Serap Erdine1, Alp Burak Çatakoğlu2 Clinic for internal disease, InterMedica; Nis-Serbia 1Department of Cardiology, Cerrahpaşa Faculty of Medicine, İstanbul University; İstanbul-Turkey 2Department of Cardiology, Liv Hospital; İstanbul-Turkey ABSTRACT Left ventricular hypertrophy (LVH) is a structural remodeling of the heart developing as a response to volume and/or pressure overload. Previous studies have shown that hypertension is not an independent factor in the development of LVH and occurrence does not depend on the length and severity of hypertension, but the role played by other comorbidities such as triglycerides, age, gender, genetics, insulin resis- tance, obesity, physical inactivity, increased salt intake and chronic stress. LVH develops through three phases: adaptive, compensatory, and pathological phase. Contractile dysfunction is reversible in the first two phases and irreversible in the third. According to the Framingham study, LVH develops in 15-20% of patients with mild arterial hypertension, and in 50% of patients with severe hypertension. The pathophysiology of LVH includes hypertrophy of cardiomyocytes, interstitial and perivascular fibrosis, coronary microangiopathy and macroangiopathy. Individuals with LVH have 2-4 times higher risk of having adverse CV events compared to patients without LVH. (Anadolu Kardiyol Derg 2014; 14: 389-95) Key words: arterial hypertension, left ventricular hypertrophy, pathophysiology, cardiovascular events Introduction increases concurrently with the increase of body size in both genders. From puberty on, the growth rate of the heart is higher Arterial hypertension is a major cause of organ damage in men than in women, implying that men and women have spe- including the heart and left ventricular hypertrophy (LVH) is a cific cardiac growth curves.
    [Show full text]